Impact Factor 4.225 | CiteScore 5.0
More on impact ›
Frontiers in Pharmacology
Neuropharmacology
Toggle navigation Section
(current)Section
Why submit?
Contact editorial office
Luis F. Callado
Christiane CHARRIAUT-MARLANGUE
Institut National de la Santé et de la Recherche Médicale (INSERM), France
Yoshitoshi Kasuya
Chiba University, Japan
The editor and reviewers' affiliations are the latest provided on their Loop research profiles and may not reflect their situation at the time of review.
Suggest a Research Topic >
XML (NLM)
Simple TEXT file
View Article Impact
Open Supplemental Data
Front. Pharmacol., 22 December 2017 | https://doi.org/10.3389/fphar.2017.00943
Sirt3 Mediates the Inhibitory Effect of Adjudin on Astrocyte Activation and Glial Scar Formation following Ischemic Stroke
Xiao Yang†, Keyi Geng†, Jinfan Zhang, Yanshuang Zhang, Jiaxiang Shao and Weiliang Xia*
State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China
In response to stroke-induced injury, astrocytes can be activated and form a scar. Inflammation is an essential component for glial scar formation. Previous study has shown that adjudin, a potential Sirt3 activator, could attenuate lipopolysaccharide (LPS)- and stroke-induced neuroinflammation. To investigate the potential inhibitory effect and mechanism of adjudin on astrocyte activation, we used a transient middle cerebral artery occlusion (tMCAO) model with or without adjudin treatment in wild type (WT) and Sirt3 knockout (KO) mice and performed a wound healing experiment in vitro. Both our in vivo and in vitro results showed that adjudin reduced astrocyte activation by upregulating Sirt3 expression. In addition, adjudin treatment after stroke promoted functional and neurovascular recovery accompanied with the decreased area of glial scar in WT mice, which was blunted by Sirt3 deficiency. Furthermore, adjudin could increase Foxo3a and inhibit Notch1 signaling pathway via Sirt3. Both the suppression of Foxo3a and overexpression of N1ICD could alleviate the inhibitory effect of adjudin in vitro indicating that Sirt3-Foxo3a and Sirt3-Notch1 signaling pathways were involved in the inhibitory effect of adjudin in wound healing experiment.
As a main cell population in the brain, astrocytes participate in lots of key signaling events including anti-oxidant activity, energy transfer, neurotransmitter up-take and recycling, ion homeostasis, trophic factor synthesis and neurovascular coupling (Abeysinghe et al., 2016). In addition to these physiological functions, astrocytes activated by brain injury such as stroke have been reported to show astrogliosis which is characterized as hypertrophic morphology and over-proliferation of astrocytes (Maragakis and Rothstein, 2006). Furthermore, glial scar formed by reactive astrocytes creates a physical barrier for axon regeneration and causes further tissue damage (Barres, 2008; Bao et al., 2012). Therefore, it is necessary to regulate the activation of astrocyte and reduce glial scar formation to overcome the physical barrier and promote neuronal regeneration in response to brain injury.
Proinflammatory cytokines have been shown to mediate astrocyte proliferation (Sriram et al., 2006). After stroke, inflammatory reaction induces the activation and proliferation of astrocytes to form a glial scar (Huang et al., 2014; Rodriguez-Grande et al., 2014). Sirtuins are a family of NAD+-dependent enzymes, involved in the control of reactive astrogliosis, which have the potential to modulate neurologic disease (Scuderi et al., 2014). Recent studies have shown that Sirt1 could alleviate astrocyte activation via regulating the MAPK pathway activation after traumatic brain injury (Li et al., 2017). As one member of sirtuins, Sirt3 can reduce reactive oxygen species (ROS) by activating forkhead box O3a (Foxo3a) and attenuate palmitate-induced inflammation (Sundaresan et al., 2009; Koyama et al., 2011). Furthermore, Foxo3a can inhibit the inflammatory cytokine-mediated activation of human astrocytes (Cui et al., 2011).
Our previous studies have shown that adjudin, as a potential Sirt3 activator, can inhibit the proliferation of cancer cells in vitro and on prostate and lung tumors inoculated in nude mice (Xia and Geng, 2016). In addition, adjudin attenuates lipopolysaccharide (LPS)- and stroke-induced neuroinflammation due to the inhibition of ERK MAPK phosphorylation and NF-κB activation (Shao et al., 2013; Liu et al., 2014). Therefore, we hypothesized that adjudin might have a protective role against glial scar formation in response to brain injury.
To determine the underlying roles of Sirt3 and adjudin in astrocyte activation after stroke, we used primary astrocytes and performed a mouse model of transient middle cerebral artery occlusion (tMCAO) in wildtype (WT) and Sirt3 knockout (KO) mice. Here, we firstly reported that Sirt3 mediated the inhibitory effect of adjudin in astrocyte activation and glial scar formation.
Reagent and Animal
DMSO was purchased from Sigma Aldrich (St. Louis, MO, USA). Adjudin was provided by Dr. C Yan Cheng of the Mary M. Wohlford Laboratory, Population Council, New York. WT mice (129/SvImJ) were purchased from Beijing Vital River Laboratory Animal Technology Corporation (Beijing, China) and Sirt3 KO mice (129-Sirt3tm1.1Fwa) were obtained from Jackson Laboratories (Bar Harbor, ME). Mice were housed in individually ventilated cages in a specific pathogen free facility, with 12 h daylight/dark cycles at 23°C. Bromodeoxyuridine (BrdU) powder (Sigma-Aldrich, St Louis, MO) was dissolved in 0.9% NaCl in a concentration of 10 mg/mL. BrdU solution was injected intraperitoneally at 50 mg/kg twice a day for 7 consecutive days 2 and 5 weeks after tMCAO.
Animal procedures were performed according to the protocol approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University, Shanghai, China. Adult male mice weighing 25–30 g (8- to 10-week-old) were used in the study. Mice were assigned to the adjudin-treated group, the DMSO-treated group or the sham group. The surgical procedure of MCAO was described previously (Yang et al., 1994). Briefly, mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) intraperitoneally. Mice were placed supinely on a heating pad (RWD Life Science, Shenzhen, China), which maintains body temperature at 37.0 ± 0.5°C. The left common carotid artery (CCA), the external carotid artery (ECA) and the internal carotid artery (ICA) were isolated. 6-0 suture (Dermalon, 1741-11, Covidien, OH, USA) coated with silicone was introduced into the ECA stump and advanced from the ICA to the opening of the middle cerebral artery (MCA) until a slight resistance was felt. At this moment, the tip of the suture was located in the anterior cerebral artery (ACA). All procedures were performed under an operating microscope (Leica, Wetzlar, Germany). The success of occlusion was characterized as the reduction of cerebral blood flow (CBF) down to 10% of baseline, which was verified by a laser Doppler flowmeter (Moor Instruments, Devon, England). The ICA was occluded for 1.5 h, followed by the removal of the suture to allow reperfusion. The sham group underwent the same procedure without suture insertion. Mice were injected with adjudin (50 mg/kg, DMSO stock dissolved in corn oil at a dilution of 1:10) or DMSO (DMSO dissolved in corn oil at a dilution of 1:10) intraperitoneally every 2 days performed 2 days after reperfusion until sacrifice.
Measurement of Infarct Volume
Mice were sacrificed 4 days after surgery; brain tissue was immediately collected and frozen into pre-chilled isopentane. The brain was cut into 20-μm-thick coronal sections. The cryosections were immersed in 0.1% cresyl violet for 30 min and rinsed in distilled water for 10 min. The infarct area in each section was calculated by the ImageJ software using the following formula: contralateral hemisphere area (mm2) - ipsilateral undamaged area (mm2). Infarct volume between two adjacent sections was calculated by this formula:
13×h×(S1+S2+S1×S2)
where S1 and S2 are the infarct areas of the two sections, and h is the two sections' distance. The total infarct volume is the sum of all infarct volume from each pair of adjacent sections.
GFAP Immunostaining
Five serial cryosections, spaced 200-μm apart (0.5 mm frontier and 0.5 mm posterior from the ischemic core), were selected from each mouse. Brain cryosections (20 μm in thickness) were fixed with methanol at −20°C for about 10 min and washed with PBS. Next, these sections were blocked with 10% BSA for 1 h. After washed with PBS, they were incubated with the primary antibodies (mouse anti-GFAP antibody, 1:300 dilution, BD Biosciences, San Jose, CA, USA) overnight at 4°C. Sections were incubated with Alexa-488-conjugated secondary antibody (1:200 dilution, Life Technologies) for 1 h, and washed with PBS. Nuclei were then stained with 4,6-diamidino-2-phenylindole (DAPI) (1:500 dilution, Beyotime Institute of Biotechnology, China). A confocal laser-scanning microscope was used to obtain confocal microscopic images (Leica TCS SP5 II, Germany).
NeuN/BrdU, and CD31/BrdU Double Immunostaining
Brains were post-fixed for 24 h followed by 48 h of immersion in 30% sucrose in PBS and immediately frozen, and then sectioned using a freezing microtome (Leica, Solms, Germany). A thickness of 20-μm coronal sections was cut. Floating coronal sections were collected in antigen protective solution, which involves 20% glycol, 30% glycerol and 50% PBS. Sections were first treated with 2 mol/L HCl for 20 min at 37°C and then neutralized with sodium borate twice each for 10 min. Sections were then treated with 0.3% Triton-X 100 in PBS for 15 min, blocked by 10% BSA, incubated with NeuN (1:100; Millipore), or CD31 (1:200; R&D) antibody at 4°C overnight. Finally, the sections were incubated with secondary antibodies (1:500; Thermo Fisher) for 60 min at room temperature. Stained sections were mounted after rinsing.
Primary Astrocyte Cell Culture
Primary astrocyte cultures were prepared from neocortical tissues of 1-day-old mice. Briefly, the cerebral hemispheres were isolated. The meninges, the hippocampus, basal ganglia, and olfactory bulb were carefully removed. Neocortical tissues were minced and incubated into 0.25% trypsin for 15 min at 37°C. Cell suspension was centrifuged at 1,000 rpm for 5 min and washed with PBS. Then the cells were resuspended in DMEM containing 10% fetal bovine serum and 100 units · ml−1/100 μg · ml−1 penicillin/streptomycin at 37°C in a humidified incubator with 5% CO2. After 24-h cell culture, the medium was replaced.
C8-D1A Cell Culture
Mouse astrocytic cell line C8-D1A was obtained from EK-Bioscience company (Shanghai, China) and cultured in DMEM (HyClone) supplemented with 10% fetal bovine serum (HyClone), 100 I.U. Penicillin and 100 mg/mL Streptomycin (Invitrogen) at 37°C in a humidified 5% CO2 incubator.
Wound Healing Assay
To gauge the ability of wound healing, nonclosed gap area was tested. 100,000 cells were seeded into 12-well plates per well and after growing to ~100% confluence, the confluent cell monolayer was scraped with a pipette tip. The length of gap was measured at 0 and 24 h after scratch. The experiments were performed in triplicate.
Oxygen-Glucose Deprivation (OGD)
Astrocytes were incubated in DMEM containing 100 units·ml−1/100 μg·ml−1 penicillin/streptomycin and 10% fetal bovine serum, and the cells washed twice and incubated in glucose-free DMEM. The cultures were transferred into a chamber filled with a gas mixture of 95% N2/5% CO2 at 37°C. Three hours after OGD, astrocytes were incubated in DMEM containing 100 units·ml−1/100 μg·ml−1 penicillin/streptomycin and 10% fetal bovine serum and reintroduced to the regular atmospheric oxygen level for an additional 24 h. In each experiment, cultures exposed to OGD were compared with normoxic controls supplied with DMEM containing glucose and maintained in standard incubation conditions.
Cell Proliferation Assay
Cell proliferation was determined by using Cell Counting Kit-8 (Yeasen, Shanghai, China). Briefly, ~10,000 cells were seeded into a well of 96-well plates. After treatment, CCK-8 solution was added to each well at the dilution of 1:10. After incubation for 1-3 h, the absorbance at 450 nm was measured by microplate reader (Synergy2, BioTek).
Cells were lysed with RIPA buffer (Millipore, Temecula, CA, USA) containing protease and phosphatase inhibitor cocktail (1:100) with 2 mM PMSF. The protein concentration was determined by using bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL, USA). 30 μg of total protein was used for this assay. Protein was separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and then it was transferred to 0.45 μm Nitrocellulose Membrane (Millipore, CA, USA).
After the overnight incubation with primary antibodies at 4°C, the membrane is hybridized with secondary antibody (1:4,000 dilution, Epitomics, China) at room temperature for 1 h. Protein signals were detected by ECL system. The primary antibodies were listed as follows: Sirt3 (1:1,000 dilution, Cell Signaling Technology, Danvers, USA); Notch1 (1:1,000 dilution, Cell Signaling Technology, Danvers, USA); Foxo3a (1:1,000, Cell Signaling Technology, Danvers, USA); β-Tubulin (1:1,000 dilution, Abcam, Hong Kong); N1ICD (1:1,000 dilution, Abcam, Hong Kong).
Total RNA was isolated from cells by RNAiso Plus (TaKaRa, Dalian, China), 1 μg of total RNA was used to synthesize first strand cDNA with PrimeScript RT reagent kit (TaKaRa). Real-time quantitative PCR was carried out on ABI 7900HT with the use of SYBR Premix Ex Taq (TaKaRa) on the basis of the following protocol: 95 for 30 s, 40 cycles consisting of 95 for °C °C 5 s and 60°C for 30 s, 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s. Primers were as follows: GFAP (sense 5′-CGGAGACGCATCACCTCTG-3′ and anti-sense 5′-AGGGAGTGGAGGAGTCATTCG-3′); Sirt3 (sense 5′-ATCCCGGACTTCAGATCCCC-3′ and anti-sense 5′-CAACATGAAAAAGGGCTTGGG-3′); Rplp0 (sense 5′-AGATTCGGGATATGCTGTTGGC-3′ and anti-sense 5′-TCGGGTCCTAGACCAGTGTTC-3′). Data were analyzed by using the comparative threshold cycle (Ct) method, and results were expressed as fold difference normalized to Rplp0.
Plasmid and SiRNA Transfection
Cells were seeded to 24-well plate or 6-well plate at the concentration of 40,000 cells or 200,000 cells per well respectively. With 24-h cell culture, transfection was then performed using Lipofectamine 3000 (Invitrogen) according to the manufacturer's protocols. siRNA sequences were as follows: Foxo3a siRNA (sense: 5′-GAACGUUGUUGGUUUGAAUdT-3′, anti-sense: 5′-AUUCAAACCAACAACGUUCdTdT-3′).
Luciferase Reporter Assay
In order to study the transcriptional level of N1ICD, C8-D1A were co-transfected by using the Lipofectamine 3000 reagent (Invitrogen) with 500 ng of the 4xCSL luciferase reporter (Figure S1) together with 500 ng of N1ICD plasmid and 10 ng of pRL-TK reference plasmid each well. After 48-h transfection, cells were treated with adjudin for 24 h and extracts were harvested. The number of replicates per experiment was 3 independently (n = 3), luciferase activity was measured using the reporter assay system (Promega, Madison, WI, USA). The N1ICD plasmid (#41730) and 4xCSL luciferase reporter (#41726) were purchased from Addgene. pRL-TK reference plasmid was provided by Pro. Gao Wei-Qiang (Shanghai jiaotong university, Shanghai, China).
Rotarod Test
To examine balance and coordination deficits, the rotarod test was introduced (Li et al., 2002). The mice were placed on the accelerating rotarod whose speed was increased from 5 to 40 rpm. The time that mice were on the rotarod was measured. The animals were trained prior to MCAO to obtain stable baselines. The test was performed on 2, 7, 14, and 35 days post-tMCAO surgery.
The data were given as mean ± standard deviation. Comparisons between two groups were analyzed by Student's t-tests. Data comparisons between multiple groups were analyzed by one-way ANOVAs with Tukey's post-hoc tests. P-values less than 0.05 considered statistically significant. All statistical analyses were performed using GraphPad Prism version 3.05 (GraphPad Software, Inc., La Jolla, CA).
Adjudin Inhibited Astrocyte Activation Following Ischemic Stroke
Our previous studies have shown adjudin protected against cerebral ischemia reperfusion and reduced infarct volume during acute phase of stroke (Liu et al., 2014). To further investigate the role of adjudin following chronic ischemic stroke, we performed adjudin administration 2 days after tMCAO. No significant differences were observed in infarct volume 4 days after ischemic stroke (Figures 1A,B). Our results showed upregulation GFAP of accompanied by hypertrophy of astrocytes in infarct region (Figure 1C). In addition, we detected the mRNA level of GFAP in infarct region, and found that GFAP expression increased significantly at different time beginning at 2 days after tMCAO (Figure 1D). To investigate the role of adjudin in astrocyte activation, we performed immunostaining for GFAP at different times (Figures 1E–G). The results showed that adjudin could significantly reduce the number of GFAP+ cell both at 4 and 7 days after stroke, indicating that astrocyte activation could be attenuated by adjudin (Figure 1H).
Figure 1. Adjudin inhibited stroke-induced astrocyte activation. Mice were treated with either DMSO or adjudin 2 days after transient middle cerebral artery occlusion (tMCAO). (A) Cresyl violet staining of brain sections from mice which were performed tMCAO and were administrated with either DMSO or adjudin 4 days after reperfusion. Line indicates infarct area. (B) Quantification of the infarct volumes. (C) The changes in astrocyte morphology were detected by immunofluorescence in vivo. The GFAP-positive astrocytes were green. (D) RT-PCR showed the GFAP expression after stroke. one-way ANOVA: *P < 0.05, ***P < 0.001 vs. the sham group (n = 4 mice per group), the sham group: control without tMCAO. (E,F) The number of GFAP+ cells decreased significantly in the adjudin-treated group compared with the DMSO-treated group at 4 and 7 days after tMCAO. (G) Hollow box represent the picture that in the infarct region of ischemic brain. (H) Quantification of GFAP+ cells. one-way ANOVA: *P < 0.05, ***P < 0.001 (n = 5 mice per group). Bars represent the mean ± SEM. Scale bar, (B) 50 μm; (E) 50 μm; (F) 50 μm.
Adjudin Inhibited Astrocyte Activation in Vitro
To further confirm the role of adjudin in astrocyte activation, we isolated primary astrocytes and performed wound healing experiments in vitro. The results showed that adjudin inhibited the scratch closure, as shown by a larger cell-free area observed 24 h after the wound (Figures 2A,B). Previous studies indicated that the astrocytes presented the characteristics in vivo after conditioned OGD (Wang et al., 2012). We found that conditioned OGD (3 h) could induce astrocytes activation and proliferation, as assessed by CCK-8 at 24 h after reperfusion (Figure 2C). Furthermore, we found that adjudin could inhibit astrocyte proliferation induced by OGD, and no differences were detected under normal condition (Figure 2C).
Figure 2. Adjudin inhibited astrocyte activation in vitro. (A) Effect of adjudin on wound healing in primary astrocytes. Dash line indicated gap area. (B) The quantification of gap area showed adjudin could significantly attenuate the wound healing 24 h after scratch. (C) The quantification the number of astrocytes showed that adjudin could significantly inhibited OGD-induced activation and proliferation 24 h reperfusion. one-way ANOVA: *P < 0.05, ***P < 0.001, ns: no significance. Bars represent the mean ± SEM.
Sirt3-Foxo3a Signaling Pathway Was Involved in the Inhibitory Effect of Adjudin on Astrocyte Activation
Our results showed that Sirt3 could be significantly upregulated by adjudin at both protein and mRNA level (Figures 3A,B). To investigate whether Sirt3 mediated the inhibitory effect of adjudin in astrocyte activation, we isolated primary astrocytes from Sirt3 KO mice. We found that Sirt3 deficiency abolished the inhibitory effect of adjudin assessed by wound healing experiment (Figures 3C,D). In addition, Foxo3a could also be upregulated by adjudin, which was attenuated by Sirt3 deficiency (Figures 3A,E). To confirm whether Foxo3a was involved in Sirt3-mediated effect of adjudin, we transfected Foxo3a siRNA in C8-D1A astrocytic cell lines (Figure 3F). The inhibitory effect of adjudin in wound healing can be blunted in Si Foxo3a cells although significant difference between two experiment groups still exist. (Figures 3G–I). These results indicated that Sirt3-Foxo3a signaling pathway might mediate the inhibitory effect of adjudin on astrocyte activation in vitro.
Figure 3. Sirt3-Foxo3a signaling pathway mediated the inhibitory effect of adjudin on wound healing in vitro. (A) Western blot showed that Sirt3 and Foxo3a protein levels were significantly upregulated by adjudin in primary astrocytes. (B) The mRNA level of Sirt3 was also upregulated by adjudin in vitro. (C) Adjudin couldn't inhibit wound healing in Sirt3 KO astrocytes. (D) The quantification of gap area in Sirt3 KO astrocytes. (E) Adjudin did not increase Foxo3a expression in Sirt3 KO astrocytes. (F) Western blot showed Foxo3a protein level was significantly decreased in FOXO3a siRNA-treated C8-D1A cells compared with NC group. t-test: **P < 0.01, ***P < 0.001, ns: no significance. Bars represent the mean ± SEM. Scale bar, (C) 500 μm. (G) Wound healing experiments were performed in C8-D1A cells, and the area of gaps were observed 24 h after scratch. (H) The gap area of C8-D1A at 0 h after scratch. (I) The quantification of gap area in C8-D1A cells showed Foxo3a deficiency attenuated the inhibitory effect of adjudin. one-way ANOVA: *P < 0.05, ***P < 0.001, ns: no significance. Bars represent the mean ± SEM. Scale bar, (G) 500 μm.
Notch1 Signaling Pathway Was Involved in Sirt3-Mediated Inhibitory Effect of Adjudin on Astrocyte Activation
Previous study have shown that Notch1 could regulate the proliferation of reactive astrocytes in the peri-infarct region after stroke (Shimada et al., 2011). We found that Notch1 and active form of N1ICD (Notch1 intracellular domain) protein levels decreased significantly in adjudin treated astrocytes, which was blunted by Sirt3 deficiency (Figure 4A). To explore transcriptional activity of N1ICD, we used 4xCSL (CBF-1–SuH–LAG-1) luciferase reporter which could reflect the activity of N1ICD-CSL-MAML transcription complex. We transfected N1ICD plasmid, 4xCSL luciferase reporter and pRL-TK reference plasmid to C8-D1A cell, and detected the activity of luciferase 24 h later. The result showed that adjudin could reduce the transcriptional activity of CSL, indicating adjudin could inhibit the downstream pathways of Notch1 (Figure 4B). To demonstrate the role of Notch1 signaling pathway in the inhibitory effect of adjudin, we transfected N1ICD plasmid in C8-D1A cells (Figure 4C). Wound healing experiment showed that N1ICD overexpression blunted the inhibitory effect of adjudin (Figures 4D–F).
Figure 4. Notch1 signaling pathway was involved in Sirt3-mediated inhibitory effect of adjudin on wound healing in vitro. (A) Western blot showed Notch1 and N1ICD protein levels were decreased by adjudin in WT astrocytes, and no significantly differences were observed in Sirt3 KO astrocytes. (B) Luciferase experiment showed adjudin significantly inhibited the transcriptional activity of N1ICD. (C) To study the role of Notch1 signaling pathway, we transfected N1ICD plasmid into C8-D1A cells. Western blot indicated N1ICD protein level. (D) We performed wound healing experiments performed in C8-D1A cells, and we observed gap area 24 h after scratch. (E) The gap area of C8-D1A at 0 h after scratch. (F) The gap area of C8-D1A at 0 h after scratch. The quantification of gap area in C8-D1A cells showed N1ICD overexpression blunted the inhibitory of adjudin. one-way ANOVA: *P < 0.05, ***P < 0.001, ns: no significance. Bars represent the mean ± SEM. Scale bar, (D) 500 μm.
Sirt3 Mediated the Neuroprotective Role of Adjudin in Ischemic Stroke
Strategies to overcome inhibitory molecules in the scar formation have been indicated to promote functional recovery (Fitch and Silver, 2008). To further study the potential involvement of adjudin in astrogliosis and scar formation, we performed tMCAO model in WT mice. GFAP immunostaining showed glial scar was narrower at 35 days after tMCAO in the adjudin-treated mice compared with that in the DMSO-treated mice, which was abolished in Sirt3 KO mice (Figures 5A,B). Similar changes were detected both in GFAP protein and mRNA levels (Figures 5C,D). Additionally, Western blot analysis showed that Sirt3 and Foxo3a were upregulated and Notch1 signaling was inhibited in adjudin-treated WT mice, as anticipated, Sirt3 deficiency also blunted this effect (Figures 5D,E). Furthermore, the rotarod test showed adjudin-treated mice performed better than the DMSO-treated mice beginning 7 days after tMCAO. However, we did not observe the neuroprotective role in Sirt3 KO mice (Figure 5F). Above results indicated glial scar played a detrimental role in functional recovery following chronic stroke.
Figure 5. Sirt3 mediated the inhibitory effect of adjudin on glial scar formation following ischemic stroke. Mice were treated with either DMSO or adjudin 2 days after tMCAO. (A) The formation of glial scar were inhibited by adjudin in WT mice 35 days after tMCAO, and Sirt3 deficiency blunted the effect of adjudin. (B) The quantification of the maximal thickness of glial scar. (C) The quantification of GFAP protein and mRNA expression. (D) Western blot showed adjudin increased Sirt3 and Foxo3a protein levels and decreased Notch1 and N1ICD protein levels in WT mice 35 days after tMCAO, which were blunted by Sirt3 deficiency. (E) The quantification of protein expression. (F) Rotarod test showed adjudin increased latency time in WT mice, and Sirt3 deficiency blunted the effect. One-way ANOVA: *P < 0.05, **P < 0.01, ns: no significance (n = 5 mice per group). Bars represent the mean ± SEM. Scale bar, (A) 100 μm.
Adjudin Promotes Neurovascular Recovery after Ischemic Stroke
Neurogenesis and angiogenesis are beneficial for the functional recovery after stroke (Li et al., 2014). To further confirm the role of adjudin in functional recovery following chronic ischemic stroke, we performed double immunostaining for NeuN/BrdU and CD31/BrdU. Compared with the control group, adjudin-treated mice displayed significantly greater numbers of NeuN+/BrdU+ and CD31+/BrdU+ cells at 35 days after tMCAO in the perifocal striatum region (Figures 6A–D), indicating that adjudin promoted neurogenesis and angiogenesis from ischemic stroke induced impairments.
Figure 6. Adjudin promotes neurovascular recovery following ischemic stroke. (A) NeuN+/BrdU+ cells were counted in perifocal region of ischemic brain, and (B) quantification of NeuN+/BrdU+ cells at 35 days after tMCAO (n = 4 per group). (C) CD31+/BrdU+ cells were counted in perifocal region of ischemic brain, and (D) quantification of CD31+/BrdU+ cells at 35 days after tMCAO (n = 4 per group). t-test: *P < 0.05. Bars represent the mean ± SEM. Scale bar, (A) 50 μm; (C) 50 μm.
After stroke, astrocytes change their morphology, proliferate, and migrate to the injury sites to form a scar (Sofroniew, 2009). In the present study, wound starch and oxygen glucose deprivation triggered the activation and proliferation of astrocytes. Our results showed that adjudin could inhibit astrocyte activation both in vitro and in vivo and Sirt3 was proved to play a crucial role in the neuroprotective function of adjudin. Furthermore, we reported that Sirt3-Foxo3a and Sirt3-Notch1 signaling pathways mediated the inhibitory effect of adjudin against astrocyte activation and glial scar formation following ischemic stroke (Figure 7).
Figure 7. Proposed neuroprotective mechanism by adjudin. Adjudin might inhibit astrocyte activation which could form a scar following stroke by increasing Sirt3 and Foxo3a expression, and inhibiting Notch1 signaling pathway. Furthermore, Foxo3a and Notch1 signaling pathways were regulated by adjudin might via Sirt3.
Globally, stroke is the second main cause of death and a leading cause of long disability. Neuroinflammation after ischemia-induced cerebral injury is known to be a key factor that contributes to glial scar formation (Jin et al., 2010) which has been shown to inhibit nerve growth and regarded as a barrier to neuronal repair (Ridet et al., 1997; Jeong et al., 2012). Our previous studies have shown that adjudin can decrease infarct volume and improve behavioral outcome via inhibiting neuroinflammation during the acute phase of ischemic stroke (Liu et al., 2014). In the current study, our data showed that the glial scar was inhibited by adjudin along with improved neurological function during the recovery phase of ischemic stroke. Since infarct size would influence the degree of astrocyte activation and scar formation following injury (Bao et al., 2012), we delayed adjudin treatment to reduce the beneficial effect of adjudin in acute phase. Although recent studies provide compelling evidence that glial scar can exert both beneficial and detrimental effect in a variety of disease processes (Anderson et al., 2016; Robel, 2016), our results indicated that glial scar plays a detrimental role in neurological function recovery following ischemic stroke.
Accumulating evidences indicate that sirtuins are related to diverse neurologic diseases including stroke and served as potential therapeutic targets in the clinical environment (Hernández-Jiménez et al., 2013; Jeśko et al., 2017). In addition, previous studies have shown that both Sirt1 activator and Sirt2-selective inhibitor were able to attenuate the activation of astrocyte as well as the production of proinflammatory cytokines (Scuderi et al., 2014). Sirt3 can be upregulated by adjudin and plays crucial roles in suppressing multiple pathologies including inflammatory responses (Lombard and Zwaans, 2014; Liu et al., 2015). Our results showed that Sirt3 deficiency attenuated the inhibitory effect of adjudin on primary astrocytes wound healing. Furthermore, Sirt3 was demonstrated to be a crucial mediator of adjudin's inhibitory effect in the formation of glial scar and neuroprotective role following ischemic stroke.
The activation of astrocyte and the formation of glial scar involve multiple signaling pathways (Koyama, 2014). Notch1 has been reported as a key factor required for reactive astrocyte activation in the infarct region as well as worsening brain damage and functional outcome after stroke (Arumugam et al., 2006; Shimada et al., 2011; LeComte et al., 2015). Recent studies have shown that Sirt3 could downregulate Notch1 in human gastric cancer, and Notch1 overexpression attenuated the inhibitory effect of Sirt3 on the proliferation of tumor cells (Wang et al., 2015). In addition, our previous studies showed that Notch1 signaling pathway related protein expression were upregulated in Sirt3 KO NSCs compared with WT group (Figure S2). We found Notch1 signaling pathway could be inhibited by adjudin accompanied with increased Sirt3 both in vivo and in vitro. The rescue experiment proved that Notch1 signaling might interact with Sirt3 and play an important role in the activation of astrocyte. Furthermore, our results showed that adjudin's inhibitory effect in wound healing can be blunted in N1ICD overexpression cells. One possible explanation of our observation is that although adjudin can inhibit the transcription activity of N1ICD, its expression level and transcriptional activity are still very high, which was able to exhibit effect in wound healing.
Foxo3a is also an important mediator for astrogliosis, negatively regulating astrocyte proliferation and reducing cytokine-mediated astrocyte proliferation (Cui et al., 2011). Sirt3 regulates Foxo3a-mediated mitochondrial biogenesis during hypoxia (Tseng et al., 2013). In addition, Sirt3-Foxo3a pathway mediates the neuroprotective effect of ketones in ischemic stroke (Yin et al., 2015). Both in vivo and in vitro, we found Foxo3a was significantly upregulated by adjudin. Sirt3 deficiency reduced the expression of Foxo3a that was enhanced by adjudin, indicating that Sirt3 functions as an upstream regulator of Foxo3a. Furthermore, knocking down Foxo3a blunted the inhibitory effect of adjudin in wound healing experiment, supporting the view that Sirt3-Foxo3a pathway contributes to the inhibitory effect of adjudin on astrocyte activation.
Neurogenesis and angiogenesis are beneficial for functional recovery. Overactive astrocytes which could form a scar adjacent to the stroke lesion breaks neurovascular coupling in structurally intact nerve. Furthermore, glial scar is not only a physical barrier to neurons trying to connect with vascular but also generates inhibitory molecules preventing axon regrowth (Abeysinghe et al., 2016). Therefore, inhibiting astrogliosis astrocytes to further reduce the glial scar is an important target for neurovascular recovery (Cai et al., 2017). Our results showed that adjudin could promote neurogenesis and angiogenesis following ischemic stroke which might be partly due to the reduction of glial scar area.
This study investigated the inhibitory effect of adjudin on astrocyte activation. We found that adjudin treatment effectively decreased glial scar area and promoted functional recovery following ischemic stroke. Moreover, we provided evidences to reveal novel Sirt3-Foxo3a and Sirt3-Notch1 pathways as the underlying mechanism.
WX was responsible for the conception and design of the study conceived the project, coordinated the study, revising it critically for important intellectual content, final approval of the version to be submitted, drafted and revised the manuscript. XY designed the study, or acquisition of data, or analysis and interpretation of data, drafted, revised the article critically for important intellectual content designed experiments, performed animal experimental procedures, rotarod test, immunofluorescent staining, real-time PCR, Western blot, cell culture, plasmid and siRNA transfection, wound scratch, luciferase reporter assay, and analyzed the data, and drafted the manuscript. KG was involved in study design, article drafting and revision, data analysis and experiment including conducted cell culture, wound scratch, immunohistological staining, Western blot, plasmid transfection, cell proliferation assay and data analysis. JZ participated in the animal experimental procedures, Western blot and immunofluorescent staining. YZ conducted part of Western blot and real-time PCR. JS assisted in the experimental design, data analysis and manuscript draft. All authors read and approved the final manuscript.
This study was supported by grants from Ministry of Science and Technology (2013CB945604), National Key Grant (2016YFC0906400), National Natural Science Foundation, China (31270032) and SJTU funding (YG2012ZD05).
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2017.00943/full#supplementary-material
Figure S1. The plasmid profile of 4xCSL-luciferase.
Figure S2. Notch1 signaling pathway related protein expression were upregulated in Sirt3 KO NSCs compared with WT group.
MCAO, middle cerebral artery occlusion; WT, wildtype; KO, knockout; LPS, lipopolysaccharide; GFAP, glial fibrillary acidic protein; N1ICD, Notch1 intracellular domain; Foxo3a, forkhead box O3a.
Abeysinghe, H. C., Phillips, E. L., Chin-Cheng, H., Beart, P. M., and Roulston, C. L. (2016). Modulating astrocyte transition after stroke to promote brain rescue and functional recovery: emerging targets include rho kinase. Int. J. Mol. Sci. 17:288. doi: 10.3390/ijms17030288
PubMed Abstract | CrossRef Full Text | Google Scholar
Anderson, M. A., Burda, J. E., Ren, Y., Ao, Y., O'Shea, T. M., Kawaguchi, R., et al. (2016). Astrocyte scar formation aids central nervous system axon regeneration. Nature 532, 195–200. doi: 10.1038/nature17623
Arumugam, T. V., Chan, S. L., Jo, D. G., Yilmaz, G., Tang, S. C., Cheng, A., et al. (2006). Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat. Med. 12, 621–623. doi: 10.1038/nm1403
Bao, Y., Qin, L., Kim, E., Bhosle, S., Guo, H., Febbraio, M., et al. (2012). CD36 is involved in astrocyte activation and astroglial scar formation. J. Cereb. Blood Flow Metab. 32, 1567–1577. doi: 10.1038/jcbfm.2012.52
Barres, B. A. (2008). The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430–440. doi: 10.1016/j.neuron.2008.10.013
Cai, H., Ma, Y., Jiang, L., Mu, Z., Jiang, Z., Chen, X., et al. (2017). Hypoxia response element-regulated MMP-9 promotes neurological recovery via glial scar degradation and angiogenesis in delayed stroke. Mol. Ther. 25, 1448–1459. doi: 10.1016/j.ymthe.2017.03.020
Cui, M., Huang, Y., Tian, C., Zhao, Y., and Zheng, J. (2011). FOXO3a inhibits TNF-alpha- and IL-1beta-induced astrocyte proliferation:Implication for reactive astrogliosis. Glia 59, 641–654. doi: 10.1002/glia.21134
Fitch, M. T., and Silver, J. (2008). CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure. Exp. Neurol. 209, 294–301. doi: 10.1016/j.expneurol.2007.05.014
Hernández-Jiménez, M., Hurtado, O., Cuartero, M. I., Ballesteros, I., Moraga, A., Pradillo, J. M., et al. (2013). Silent information regulator 1 protects the brain against cerebral ischemic damage. Stroke 44, 2333–2337. doi: 10.1161/STROKEAHA.113.001715
Huang, L., Wu, Z. B., Zhuge, Q., Zheng, W., Shao, B., Wang, B., et al. (2014). Glial scar formation occurs in the human brain after ischemic stroke. Int. J. Med. Sci. 11, 344–348. doi: 10.7150/ijms.8140
Jeong, S. R., Kwon, M. J., Lee, H. G., Joe, E. H., Lee, J. H., Kim, S. S., et al. (2012). Hepatocyte growth factor reduces astrocytic scar formation and promotes axonal growth beyond glial scars after spinal cord injury. Exp. Neurol. 233, 312–322. doi: 10.1016/j.expneurol.2011.10.021
Jeśko, H., Wencel, P., Strosznajder, R. P., and Strosznajder, J. B. (2017). Sirtuins and their roles in brain aging and neurodegenerative disorders. Neurochem. Res. 42, 876–890. doi: 10.1007/s11064-016-2110-y
Jin, R., Yang, G., and Li, G. (2010). Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol. 87, 779–789. doi: 10.1189/jlb.1109766
Koyama, T., Kume, S., Koya, D., Araki, S., Isshiki, K., Chin-Kanasaki, M., et al. (2011). SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. Free Radic. Biol. Med. 51, 1258–1267. doi: 10.1016/j.freeradbiomed.2011.05.028
Koyama, Y. (2014). Signaling molecules regulating phenotypic conversions of astrocytes and glial scar formation in damaged nerve tissues. Neurochem. Int. 78, 35–42. doi: 10.1016/j.neuint.2014.08.005
LeComte, M. D., Shimada, I. S., Sherwin, C., and Spees, J. L. (2015). Notch1-STAT3-ETBR signaling axis controls reactive astrocyte proliferation after brain injury. Proc. Natl. Acad. Sci. U.S.A. 112, 8726–8731. doi: 10.1073/pnas.1501029112
Li, D., Liu, N., Zhao, H. H., Zhang, X., Kawano, H., Liu, L., et al. (2017). Interactions between Sirt1 and MAPKs regulate astrocyte activation induced by brain injury in vitro and in vivo. J. Neuroinflammation 14, 67. doi: 10.1186/s12974-017-0841-6
Li, Y., Chen, J., Chen, X. G., Wang, L., Gautam, S. C., Xu, Y. X., et al. (2002). Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 59, 514–523. doi: 10.1212/WNL.59.4.514
Li, Y., Huang, J., He, X., Tang, G., Tang, Y. H., Liu, Y., et al. (2014). Postacute stromal cell-derived factor-1alpha expression promotes neurovascular recovery in ischemic mice. Stroke 45, 1822–1829. doi: 10.1161/STROKEAHA.114.005078
Liu, T. F., Vachharajani, V., Millet, P., Bharadwaj, M. S., Molina, A. J., McCall, C. E., et al. (2015). Sequential actions of SIRT1-RELB-SIRT3 coordinate nuclear-mitochondrial communication during immunometabolic adaptation to acute inflammation and sepsis. J. Biol. Chem. 290, 396–408. doi: 10.1074/jbc.M114.566349
Liu, T., Zhang, T., Yu, H., Shen, H., and Xia, W. (2014). Adjudin protects against cerebral ischemia reperfusion injury by inhibition of neuroinflammation and blood-brain barrier disruption. J. Neuroinflammation 11:107. doi: 10.1186/1742-2094-11-107
Lombard, D. B., and Zwaans, B. M. (2014). SIRT3: as simple as it seems? Gerontology 60, 56–64. doi: 10.1159/000354382
Maragakis, N. J., and Rothstein, J. D. (2006). Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2, 679–689. doi: 10.1038/ncpneuro0355
Ridet, J. L., Malhotra, S. K., Privat, A., and Gage, F. H. (1997). Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20, 570–577. doi: 10.1016/S0166-2236(97)01139-9
Robel, S. (2016). Astroglial scarring and seizures: a cell biological perspective on epilepsy. Neuroscientist. doi: 10.1177/1073858416645498. [Epub ahead of print].
Rodriguez-Grande, B., Swana, M., Nguyen, L., Englezou, P., Maysami, S., Allan, S. M., et al. (2014). The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury. J. Cereb. Blood Flow Metab. 34, 480–488. doi: 10.1038/jcbfm.2013.224
Scuderi, C., Stecca, C., Bronzuoli, M. R., Rotili, D., Valente, S., Mai, A., et al. (2014). Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer's disease. Front. Pharmacol. 5:89. doi: 10.3389/fphar.2014.00089
Shao, J., Liu, T., Xie, Q. R., Zhang, T., Yu, H., Wang, B., et al. (2013). Adjudin attenuates lipopolysaccharide (LPS)- and ischemia-induced microglial activation. J. Neuroimmunol. 254, 83–90. doi: 10.1016/j.jneuroim.2012.09.012
Shimada, I. S., Borders, A., Aronshtam, A., and Spees, J. L. (2011). Proliferating reactive astrocytes are regulated by Notch-1 in the peri-infarct area after stroke. Stroke 42, 3231–3237. doi: 10.1161/STROKEAHA.111.623280
Sofroniew, M. V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638–647. doi: 10.1016/j.tins.2009.08.002
Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., O'Callaghan, J. P., et al. (2006). Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J. 20, 670–682. doi: 10.1096/fj.05-5106com
Sundaresan, N. R., Gupta, M., Kim, G., Rajamohan, S. B., Isbatan, A., Gupta, M. P., et al. (2009). Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 119, 2758–2771. doi: 10.1172/JCI39162
Tseng, A. H., Shieh, S. S., and Wang, D. L. (2013). SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic. Biol. Med. 63, 222–234. doi: 10.1016/j.freeradbiomed.2013.05.002
Wang, L., Wang, W. Y., and Cao, L. P. (2015). SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1. Int. J. Clin. Exp. Med. 8, 5263–5271.
PubMed Abstract | Google Scholar
Wang, R., Zhang, X., Zhang, J., Fan, Y., Shen, Y., Hu, W., et al. (2012). Oxygen-glucose deprivation induced glial scar-like change in astrocytes. PLoS ONE 7:e37574. doi: 10.1371/journal.pone.0037574
Xia, W., and Geng, K. (2016). A sirtuin activator and an anti-inflammatory molecule-multifaceted roles of adjudin and its potential applications for aging-related diseases. Semin. Cell Dev. Biol. 59, 71–78. doi: 10.1016/j.semcdb.2016.07.020
Yang, G., Chan, P. H., Chen, J., Carlson, E., Chen, S. F., Weinstein, P., et al. (1994). Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke 25, 165–170. doi: 10.1161/01.STR.25.1.165
Yin, J., Han, P., Tang, Z., Liu, Q., and Shi, J. (2015). Sirtuin 3 mediates neuroprotection of ketones against ischemic stroke. J. Cereb. Blood Flow Metab. 35, 1783–1789. doi: 10.1038/jcbfm.2015.123
Keywords: ischemic stroke, adjudin, Sirt3, astrocyte activation, functional recovery
Citation: Yang X, Geng K, Zhang J, Zhang Y, Shao J and Xia W (2017) Sirt3 Mediates the Inhibitory Effect of Adjudin on Astrocyte Activation and Glial Scar Formation following Ischemic Stroke. Front. Pharmacol. 8:943. doi: 10.3389/fphar.2017.00943
Received: 12 October 2017; Accepted: 11 December 2017;
Published: 22 December 2017.
Luis F. Callado, University of the Basque Country (UPV/EHU), Spain
Christiane Charriaut-Marlangue, Institut National de la Santé et de la Recherche Médicale, France
Yoshitoshi Kasuya, Chiba University, Japan
Copyright © 2017 Yang, Geng, Zhang, Zhang, Shao and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Weiliang Xia, wlxia@sjtu.edu.cn
People also looked at
There is no supplementary material currently available for this article
Loading supplemental data...
Notify me on publication
If you already have an account, please login.
You don't have a Frontiers account ? You can register here.
Select one of your emails
You have multiple emails registered with Frontiers:
Comment deleted on